News & Events
Crinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new...
READ MORECrinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
Event Date: November 12, 2024
READ MORECrinetics Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new...
READ MORECrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Crinetics announces the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price...
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announces that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of...
READ MORECrinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
Crinetics announces the submission of a New Drug Application to the FDA for its investigational drug, paltusotine, for the treatment...
READ MORE2024 Cantor Global Healthcare Conference
Event Date: September 18, 2024
READ MORECrinetics Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to fifteen new...
READ MORECrinetics Pharmaceuticals to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
Event Date: September 4, 2024
READ MORECrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Crinetics management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.